BIOMAT Database Logo BIOMAT Database Logo

Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. 1998

P Vic, and S Ategbo, and D Turck, and M O Husson, and V Launay, and G A Loeuille, and A Sardet, and A Deschildre, and D Druon, and C Arrouet-Lagande
Department of Paediatrics, Lille University Hospital, France.

OBJECTIVE To compare once daily with thrice daily tobramycin for treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. METHODS 22 patients with cystic fibrosis, mean (SD) age 11 (3.4) years (range 5.6-19.3), with pulmonary pseudomonas exacerbations were randomly assigned to receive a 14 day course of tobramycin (15 mg/kg/day) either in three infusions (group A) (n = 10) or a single daily infusion (group B) (n = 12), combined with ceftazidime (200 mg/kg/day as three intravenous injections). Efficacy was assessed by comparison of pulmonary, nutritional, and inflammatory indices on days 1 and 14. Cochlear and renal tolerance were assessed on days 1 and 14. Tobramycin concentration was measured in serum and sputum 1, 2, 3, 4, 8, and 24 hours after the start of the infusion. Analysis was by non-parametric Wilcoxon test. RESULTS Variables improving (p < 0.05) in both groups A and B were, respectively: weight/height (+4% and +3.1%), plasma prealbumin (+66 and +63 mg/l), forced vital capacity (FVC) (+14% and +11%), forced expiratory volume in one second (+15% and +14%), and forced expiratory flow between 25% and 75% of FVC (+13% and +21%). Improvement was not significantly different between groups. Renal and cochlear indices remained within the normal range. Serum peak concentration of tobramycin on day 1 was 13.2 (7.1) mg/l in group A and 42.5 (11.2) mg/l in group B (p < 0.001); serum trough was 1.1 (0.8) mg/l in group A and 0.3 (0.2) mg/l in group B (p < 0.01). Tobramycin concentrations in sputum were two to three times higher in group B than group A. CONCLUSIONS Once daily tobramycin combined with three injections of ceftazidime is safe and effective for the treatment of pseudomonas exacerbations in cystic fibrosis patients.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

P Vic, and S Ategbo, and D Turck, and M O Husson, and V Launay, and G A Loeuille, and A Sardet, and A Deschildre, and D Druon, and C Arrouet-Lagande
Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
February 1999, Archives of disease in childhood,
P Vic, and S Ategbo, and D Turck, and M O Husson, and V Launay, and G A Loeuille, and A Sardet, and A Deschildre, and D Druon, and C Arrouet-Lagande
Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients.
May 1996, The Journal of antimicrobial chemotherapy,
P Vic, and S Ategbo, and D Turck, and M O Husson, and V Launay, and G A Loeuille, and A Sardet, and A Deschildre, and D Druon, and C Arrouet-Lagande
Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.
May 2001, Pediatric pulmonology,
P Vic, and S Ategbo, and D Turck, and M O Husson, and V Launay, and G A Loeuille, and A Sardet, and A Deschildre, and D Druon, and C Arrouet-Lagande
Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.
April 2000, Antimicrobial agents and chemotherapy,
P Vic, and S Ategbo, and D Turck, and M O Husson, and V Launay, and G A Loeuille, and A Sardet, and A Deschildre, and D Druon, and C Arrouet-Lagande
Once-daily tobramycin monotherapy in cystic fibrosis.
May 2002, Pediatric pulmonology,
P Vic, and S Ategbo, and D Turck, and M O Husson, and V Launay, and G A Loeuille, and A Sardet, and A Deschildre, and D Druon, and C Arrouet-Lagande
Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis.
November 1997, Chest,
P Vic, and S Ategbo, and D Turck, and M O Husson, and V Launay, and G A Loeuille, and A Sardet, and A Deschildre, and D Druon, and C Arrouet-Lagande
The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis.
July 1998, The Journal of antimicrobial chemotherapy,
P Vic, and S Ategbo, and D Turck, and M O Husson, and V Launay, and G A Loeuille, and A Sardet, and A Deschildre, and D Druon, and C Arrouet-Lagande
Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis.
September 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
P Vic, and S Ategbo, and D Turck, and M O Husson, and V Launay, and G A Loeuille, and A Sardet, and A Deschildre, and D Druon, and C Arrouet-Lagande
Does Circadian Rhythm Affect the Pharmacokinetics of Once-Daily Tobramycin in Adults With Cystic Fibrosis?
August 2020, Therapeutic drug monitoring,
P Vic, and S Ategbo, and D Turck, and M O Husson, and V Launay, and G A Loeuille, and A Sardet, and A Deschildre, and D Druon, and C Arrouet-Lagande
Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis.
August 2016, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!